Astaxanthin Boosts Endurance and Cuts Muscle Damage in Chronic Exercise Fatigue

Chronic exercise fatigue occurs when accumulated fatigue from repeated training cannot be adequately resolved, impairing performance and recovery. Finding safe, effective nutritional strategies to delay fatigue onset and speed recovery is a priority in sports medicine. Astaxanthin, a lipophilic carotenoid derived from microalgae, is one of nature's most potent antioxidants and has shown promise in acute exercise models, but its role in chronic fatigue had not been systematically examined.

This study used 20 male Sprague-Dawley rats trained progressively on a treadmill for 8 weeks (10–30 m/min, 0–5° incline, 20–40 min/session, 5 days/week) to establish a chronic exercise fatigue model. Half received astaxanthin by gavage (3 mg/100 g body weight/day in soybean oil); the other half received soybean oil alone. After 8 weeks, subgroups either rested or underwent a single exhaustive treadmill bout (20 m/min, 0° incline), creating four groups: AX (astaxanthin, no exhaustion), Con (control, no exhaustion), AXE (astaxanthin plus exhaustion), and E (control plus exhaustion). Tissues and blood were collected 24 hours after the final session.

Astaxanthin-treated rats ran significantly longer before exhaustion (p<0.001). Serum BUN and CK — markers of protein catabolism and muscle damage — were significantly lower in the AX group (p<0.01 each), while liver glycogen and serum NEFA were significantly higher (p<0.01 and p<0.001), indicating better energy substrate preservation and enhanced lipid mobilization. Antioxidant capacity was meaningfully improved: serum CAT and GSH-Px activities rose significantly (p<0.01 each), and the GSH/GSSG ratio increased (p<0.05), reflecting reduced oxidative stress. Mitochondrial membrane potential and the ST3/ST4 respiratory control ratio in gastrocnemius muscle were both significantly elevated in the AX group (p<0.01 and p<0.001), pointing to preserved mitochondrial integrity and oxidative phosphorylation efficiency.

In the post-exhaustion recovery groups, AXE rats showed significantly lower BUN (p<0.001) and higher liver glycogen and NEFA (p<0.001 each) versus exhaustion controls, and GSH-Px was significantly elevated (p<0.001), though CAT and GSH/GSSG did not reach significance. The authors propose that astaxanthin's lipophilicity allows it to accumulate in mitochondrial membranes, protecting carnitine palmitoyltransferase-1 (CPT1) from oxidative damage and thereby enhancing long-chain fatty acid transport and lipid oxidation during sustained exercise.

While the results are mechanistically coherent and statistically robust within the animal model, the study is limited by small group sizes (n=5 per group), absence of direct ROS measurement in mitochondria, and the inherent challenge of translating rat gavage dosing to human supplementation protocols. Nonetheless, the findings provide a solid mechanistic rationale for astaxanthin as a fatigue-management supplement worthy of controlled human trials.